Marker Therapeutics arrives at its May 21 Q1 earnings call in a markedly different position than it held six weeks ago — short sellers have been cutting exposure sharply, the stock slipped another 11% over the past month, and a beat on last night's preliminary numbers has done little to arrest the drift.
The most striking development in the positioning data is just how aggressively short sellers have unwound. Short interest collapsed roughly 60% over the past month, falling to just under 1% of the free float. Within the week alone the position shrank by nearly a third. That is a story of shorts taking profits or exiting ahead of a scheduled catalyst, not a squeeze. With the ORTEX short score at 32.8 — a moderate reading — the overall signal is that bearish conviction has faded rather than built. Days to cover remain minimal at around two days, which removes any overhang from the lending market regardless of what the print delivers.
The borrow market corroborates the relaxed tone. Cost to borrow has drifted between 1.4% and 2.4% over the past six weeks — cheap by any clinical-stage biotech standard — and has eased roughly 16% from a month ago. That kind of borrowing cost does not suggest a hard-to-borrow situation; shares are plentiful for anyone who wants to put on a new short. Utilization is running at just 11%, down sharply from a 52-week peak of nearly 80% hit earlier in the year. The lending pool is effectively wide open at present.
The Street, to the extent it is paying attention to MRKR, sits uniformly in buy territory — though the coverage base is thin and the most recent analyst data is dated. HC Wainwright initiated with a Buy in December 2025 at a $10 target; Canaccord and WBB have comparable constructive ratings. With the stock trading at $1.42 and consensus targets implying an implausibly wide implied upside, investors should treat those price targets as stale reflections of earlier-stage clinical expectations rather than current conviction. The analyst return potential metric sits near 454% by screen, but that figure is a mathematical artifact of a sub-$2 stock versus targets set before a prolonged re-rating lower. What matters more is that no analyst has downgraded or initiated a sell — passive tolerance rather than active endorsement. The company posted a Q1 EPS of $(0.16), beating the $(0.18) estimate by $0.02, and ORTEX flagged the result with a high-importance score on May 15 — a small but clean beat that precedes the formal earnings call set for May 21.
The earnings history is relevant context. The four most recent post-report sessions showed moves of +6.8%, +5.6%, -2.9%, and +13.7% on day one. The five-day drift after the November 2025 print reached +24.7%. MRKR is a micro-cap with a market value around $24 million; it can move sharply on thin volume when a catalyst lands. The Q1 beat is already public, which limits upside surprise on the headline number, but the May 21 call itself — with a full year of results and clinical updates — could still drive volatility well beyond what the quiet lending market currently prices in.
The setup into the formal call is therefore one of light positioning meeting a known catalyst. Shorts have already largely stepped back. Borrow is cheap and available in size. The institutional register is led by New Enterprise Associates at roughly 10% — a long-term holder that added shares in December 2024 — with Vanguard quietly adding 79,500 shares through March 2026. What to watch on May 21 is whether clinical pipeline commentary shifts the narrative beyond the beat-and-release dynamic that has characterised recent prints, and whether the revenue trend — which fell from $6.6 million to $3.6 million year-on-year in 2025 — shows any sign of stabilising.
See the live data behind this article on ORTEX.
Open MRKR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
